CrystalGenomics Inc
KOSDAQ:083790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CrystalGenomics Inc
Cash from Financing Activities
CrystalGenomics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CrystalGenomics Inc
KOSDAQ:083790
|
Cash from Financing Activities
-₩3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Financing Activities
₩339.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash from Financing Activities
₩123.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash from Financing Activities
₩3.9B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Financing Activities
₩155.6B
|
CAGR 3-Years
276%
|
CAGR 5-Years
15%
|
CAGR 10-Years
103%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash from Financing Activities
₩32.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
122%
|
CAGR 10-Years
N/A
|
|
CrystalGenomics Inc
Glance View
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.
See Also
What is CrystalGenomics Inc's Cash from Financing Activities?
Cash from Financing Activities
-3.3B
KRW
Based on the financial report for Dec 31, 2025, CrystalGenomics Inc's Cash from Financing Activities amounts to -3.3B KRW.
